Bayer Schering Pharma AG has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending Zevalin® ([90Y]-ibritumomab tiuxetan) as consolidation th
read more » Discuss Add this link to...Bury Add to:
| Bookmarks
The European Commission has extended the marketing authorization for Zevalin® ([90Y]-ibritumomab tiuxetan) in Europe. Zevalin can now be used in the course of a first-line therapy after remission ind
read more » Discuss Add this link to...Bury Add to:
| Bookmarks